PCSK1 Overexpression in Rectal Cancer Correlates with Poor Response to Preoperative Chemoradiotherapy and Prognosis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.2133226742998
   PubMed Web of Science ®Google Scholar
• Lee YC, Lee YL, Chuang JP, Lee JC. Differences in survival between colon and rectal cancer from SEER data. PLoS One. 2013;8(11):e78709. doi:10.1371/journal.pone.007870924265711
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740. doi:10.1056/NEJMoa04069415496622
   PubMed Web of Science ®Google Scholar
• van den Brink M, Stiggelbout AM, van den Hout WB, et al. Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol. 2004;22(19):3958–3964. doi:10.1200/JCO.2004.01.02315459218
   PubMed Web of Science ®Google Scholar
• Li XM, Ling Y, Lu DR, et al. The obesity-related polymorphism PCSK1 rs6235 is associated with essential hypertension in the Han Chinese population. Hypertens Res. 2012;35(10):994–999. doi:10.1038/hr.2012.7922592666
   PubMed Web of Science ®Google Scholar
• Gu Q, Yazdanpanah M, van Hoek M, et al. Common variants in PCSK1 influence blood pressure and body mass index. J Hum Hypertens. 2015;29(2):82–86. doi:10.1038/jhh.2014.5925031086
   PubMed Web of Science ®Google Scholar
• Choquet H, Stijnen P, Creemers JW. Genetic and functional characterization of PCSK1. Methods Mol Biol. 2011;768:247–253.21805247
   PubMedGoogle Scholar
• Ramos-Molina B, Martin MG, Lindberg I. PCSK1 variants and human obesity. Prog Mol Biol Transl Sci. 2016;140:47–74.27288825
   PubMed Web of Science ®Google Scholar
• Khatib AM, Siegfried G, Chretien M, Metrakos P, Seidah NG. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol. 2002;160(6):1921–1935. doi:10.1016/S0002-9440(10)61140-612057895
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang S, Li P, et al. Pancreatic cancer-derived exosomes suppress the production of GIP and GLP-1 from STC-1 cells in vitro by down-regulating the PCSK1/3. Cancer Lett. 2018;431:190–200. doi:10.1016/j.canlet.2018.05.02729800682
   PubMed Web of Science ®Google Scholar
• Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688–8696. doi:10.1200/JCO.2005.02.132916246976
   PubMed Web of Science ®Google Scholar
• Li C-F, He H-L, Wang J-Y, et al. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. J Clin Pathol. 2014;67(12):1056–1061. doi:10.1136/jclinpath-2014-20255125271212
   PubMed Web of Science ®Google Scholar
• Sheu MJ, Li CF, Lin CY, et al. Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy. Tumour Biol. 2014;35(8):7755–7763. doi:10.1007/s13277-014-2032-824810927
   PubMedGoogle Scholar
• Rezaeian AH, Li CF, Wu CY, et al. A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1alpha activation, tumorigenesis and metastasis. Nat Cell Biol. 2017;19(1):38–51. doi:10.1038/ncb344527918549
   PubMed Web of Science ®Google Scholar
• Longuespee R, Couture F, Levesque C, et al. Implications of proprotein convertases in ovarian cancer cell proliferation and tumor progression: insights for PACE4 as a therapeutic target. Transl Oncol. 2014;7(3):410–419. doi:10.1016/j.tranon.2014.04.008
   PubMed Web of Science ®Google Scholar
• Du J, Keegan BP, North WG. Key peptide processing enzymes are expressed by breast cancer cells. Cancer Lett. 2001;165(2):211–218. doi:10.1016/S0304-3835(01)00409-811275371
   PubMed Web of Science ®Google Scholar
• Chretien M, Mbikay M. 60 YEARS OF POMC: from the prohormone theory to pro-opiomelanocortin and to proprotein convertases (PCSK1 to PCSK9). J Mol Endocrinol. 2016;56(4):T49–T62. doi:10.1530/JME-15-026126762158
   PubMed Web of Science ®Google Scholar
• Basak A, Chen A, Majumdar S, Smith HP. In vitro assay for protease activity of proprotein convertase subtilisin kexins (PCSKs): an overall review of existing and new methodologies. Methods Mol Biol. 2011;768:127–153.21805240
   PubMedGoogle Scholar
• Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ. Proprotein convertases: “master switches” in the regulation of tumor growth and progression. Mol Carcinog. 2005;44(3):151–161. doi:10.1002/mc.2013416167351
   PubMed Web of Science ®Google Scholar
• Chretien M, Seidah NG, Basak A, Mbikay M. Proprotein convertases as therapeutic targets. Expert Opin Ther Targets. 2008;12(10):1289–1300. doi:10.1517/14728222.12.10.128918781827
   PubMed Web of Science ®Google Scholar
• Kajiwara H, Itoh Y, Itoh J, Yasuda M, Osamura RY. Immunohistochemical expressions of prohormone convertase (PC)1/3 and PC2 in carcinoids of various organs. Tokai J Exp Clin Med. 1999;24(1):13–20.10530621
   PubMedGoogle Scholar
• Cheng M, Watson PH, Paterson JA, Seidah N, Chretien M, Shiu RP. Pro-protein convertase gene expression in human breast cancer. Int J Cancer. 1997;71(6):966–971. doi:10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.0.CO;2-49185698
   PubMed Web of Science ®Google Scholar
• Yoon J, Beinfeld MC. Prohormone convertase 1 is necessary for the formation of cholecystokinin 8 in Rin5F and STC-1 cells. J Biol Chem. 1997;272(14):9450–9456. doi:10.1074/jbc.272.14.94509083084
   PubMed Web of Science ®Google Scholar
• Itoh Y, Tanaka S, Takekoshi S, Itoh J, Osamura RY. Prohormone convertases (PC1/3 and PC2) in rat and human pancreas and islet cell tumors: subcellular immunohistochemical analysis. Pathol Int. 1996;46(10):726–737. doi:10.1111/j.1440-1827.1996.tb03541.x8916141
   PubMed Web of Science ®Google Scholar
• Mbikay M, Sirois F, Yao J, Seidah NG, Chretien M. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer. 1997;75(10):1509–1514. doi:10.1038/bjc.1997.2589166946
   PubMed Web of Science ®Google Scholar
• Tzimas GN, Chevet E, Jenna S, et al. Abnormal expression and processing of the proprotein convertases PC1 and PC2 in human colorectal liver metastases. BMC Cancer. 2005;5:149. doi:10.1186/1471-2407-5-14916293189
   PubMed Web of Science ®Google Scholar
• Horsch D, Day R, Seidah NG, Weihe E, Schafer MK. Immunohistochemical localization of the pro-peptide processing enzymes PC1/PC3 and PC2 in the human anal canal. Peptides. 1997;18(5):755–760. doi:10.1016/S0196-9781(96)00029-09213372
   PubMed Web of Science ®Google Scholar
• Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028–1040. doi:10.1038/nm.280722772564
   PubMed Web of Science ®Google Scholar
• Teresa Pinto A, Laranjeiro Pinto M, Patricia Cardoso A, et al. Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities. Sci Rep. 2016;6:18765. doi:10.1038/srep1876526735768
   PubMed Web of Science ®Google Scholar
• Stijnen P, Tuand K, Varga TV, Franks PW, Aertgeerts B, Creemers JW. The association of common variants in PCSK1 with obesity: a HuGE review and meta-analysis. Am J Epidemiol. 2014;180(11):1051–1065. doi:10.1093/aje/kwu23725355447
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22(4):648–657. doi:10.1200/JCO.2004.07.12114966087
   PubMed Web of Science ®Google Scholar
• You JF, Tang R, Changchien CR, et al. Effect of body mass index on the outcome of patients with rectal cancer receiving curative anterior resection: disparity between the upper and lower rectum. Ann Surg. 2009;249(5):783–787.19387325
   PubMed Web of Science ®Google Scholar
• Vares G, Wang B, Ishii-Ohba H, Nenoi M, Nakajima T. Diet-induced obesity modulates epigenetic responses to ionizing radiation in mice. PLoS One. 2014;9(8):e106277. doi:10.1371/journal.pone.010627725171162
   PubMed Web of Science ®Google Scholar
• Incio J, Tam J, Rahbari NN, et al. PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clin Cancer Res. 2016;22(12):2993–3004. doi:10.1158/1078-0432.CCR-15-183926861455
   PubMed Web of Science ®Google Scholar
• Lee SY, Kim CH, Kim YJ, Kwak HD, Ju JK, Kim HR. Obesity as an independent predictive factor for pathologic complete response after neoadjuvant chemoradiation in rectal cancer. Ann Surg Treat Res. 2019;96(3):116–122.30838183
   PubMed Web of Science ®Google Scholar
• Ho V, Chung L, Singh A, et al. Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis. BMC Cancer. 2018;18(1):869. doi:10.1186/s12885-018-4776-930176843
   PubMedGoogle Scholar
• Huang Y, Zhang Y, Li J, Liu G. Charlson comorbidity index for evaluation of the outcomes of elderly patients undergoing laparoscopic surgery for colon cancer. J BUON. 2017;22(3):686–691.28730775
   PubMed Web of Science ®Google Scholar
• Maruoka D, Arai M, Ishigami H, et al. Sporadic nonampullary duodenal adenoma/carcinoma is associated with not only colon adenoma/carcinoma but also gastric cancer: association of location of duodenal lesions with comorbid diseases. Scand J Gastroenterol. 2015;50(3):333–340. doi:10.3109/00365521.2014.100339925582657
   PubMed Web of Science ®Google Scholar